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Purpose: To develop and validate a new, simple, sensitive, rapid, cost-effective and accurate reverse 
phase-high performance liquid chromatography (RP-HPLC) method for the determination of aprepitant 
(APT) in capsule dosage form. 
Methods: The method developed for the determination of APT in capsule formulation involved using 
RP-HPLC which incorporated a C18 column 250 x 2.5 mm i.d, 5 µm particle size, in isocratic mode, with 
mobile phase comprising of methanol: water in the  ratio of 90:10 (v/v). The flow rate was 1 mL/min and 
the detection was monitored at 220 nm. The total run time was 10 min and the column was maintained 
at ambient temperature.  
Results: APT was eluted in the given mobile phase with a retention time (tr) of 4.473 min. The linearity 
for the quantification of APT was 0.1 - 10 µg/mL (R
2
 =0.989, Y= 33032x + 71501) with coefficients of 
variation (based on mean peak area for six replicate injections) in the range 0.04 to 0.132. The limits of 
detection and of quantification were 0.028 and 0.094 µg/mL, respectively. Recovery of the method was 
99.56 - 100.5 % while the relative standard deviation (RSD) of intra-day and inter-day precision was 
0.85 and 1.05, respectively.  System precision and method precision were 0.013 and 1.400 %, 
respectively. The specificity data of the proposed method indicated that excipients in the capsules did 
not interfere with the drug peak. Furthermore, the well-shaped peaks buttressed the specificity of the 
method. 
Conclusion: The proposed RP-HPLC method is simple, sensitive, rapid, cost-effective and accurate for 
the determination of APT in both bulk materials and pharmaceutical dosage forms. 
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INTRODUCTION 
 
Aprepitant (APT) is substance P/neurokinin 1 




triazol-3-one (Fig 1).   
 
 Fig 1: Chemical structure of aprepitant  
 
It is a white to off-white crystalline solid, with 
a molecular weight of 534.43 and empirical 
formula C23H21F7N4O3. It is a selective high-
affinity antagonist of human substance 
P/neurokinin 1 (NK1) receptors and has little 
or no affinity for serotonin (5-HT3), dopamine, 
and corticosteroid receptors, which are the 
targets of existing therapies for 
chemotherapy-induced nausea and vomiting 
(CINV) as well as postoperative nausea and 
vomiting (PONV) [1]. APT has been shown in 
animal models to inhibit emesis induced by 
cytotoxic chemotherapeutic agents, such as 
cisplatin, via central actions.  
 
Animal and human positron emission 
tomography (PET) studies with APT have 
shown that it crosses the blood brain barrier 
and occupies brain NK 1 receptors [2]. 
Animal and human studies show that APT 
augments the antiemetic activity of the 5-HT3 
receptor antagonist, ondansetron, and the 
corticosteroid, dexamethasone, and inhibits 
both the acute and delayed phases of 
cisplatin-induced emesis.  
 
It has recently been demonstrated that 
substance P (SP) and neuro kinin -1 (NK-1) 
receptor antagonists induce cell proliferation 
and cell inhibition in human melanoma cells. 
Literature review reveals that very few 
analytical methods have been established for 
the determination of APT and its metabolites 
in human plasma [3,4]. They include HPLC 
chromatographic reactor approach for 
investigating the hydrolytic stability of a 
pharmaceutical compound [5], estimation of 
APT in rhesus macaque plasma [6], 
characterization and quantitation of APT drug 
substance polymorphs by attenuated total 
reflectance Fourier transform infrared 
spectroscopy [7], and estimation of APT by 
RP-HPLC [8]. To the best of our knowledge, 
only one RP-HPLC method has been 
reported in the literature [8].  
This work is an attempt to develop a simple, 
sensitive, rapid, accurate and low-cost RP-
HPLC method for the determination of APT in 
solid dosage forms with the advantage of 
shorter retention time, run-time and low-cost 






A pure sample of APT (99.96 %) was 
received as a gift from Dr Reddys 
Laboratories Pvt Ltd, Hyderabad, India. 
HPLC grade water and methanol (Qualigens 
Fine Chemicals, Mumbai India), electronic 
analytical balance (Dhona, Delhi, India), 
micropipette (Inlabs, Mumbai, India,10 – 100 
µl) and Aprecap® capsules (80 mg, 
Glenmark Pharmaceuticals Ltd, India) were 
employed in the study. All the glassware 
employed in the work were cleaned with hot 
water, then acetic anhydride and finally 
acetone, and dried in a hot air oven until 
used. The working environment was 
maintained at 18-22 
o
C. The chemical 
structure and purity of the sample obtained 
were confirmed by TLC, IR, melting point, 
DSC studies. 
 
Instrumentation and chromatographic 
conditions  
 
The HPLC system consisted of an Agilent LC 
1200 HPLC pump, solvent degasser, a 
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variable wavelength detector with deuterium 
lamp, a rheodyne injector and EZ chromelite 
software. Isocratic elution of the mobile 
phase, comprising of methanol and water in 
the ratio of 90: 10(v/v), at a flow rate of 
1mL/min was performed on a C18 column 
(250x 4.6 mm i.d, 5µm particle size). The run 
time was set at 10 min and column 
temperature was maintained at ambient. The 
volume of injection was 20 µL; prior to 
injection of analyte, the column was 
equilibrated for 30 - 40 min with mobile 




The analytical method was validated for 
linearity, accuracy, precision, limit of 
detection (LOD), limit of quantification (LOQ), 
specificity, robustness, and ruggedness, in 
accordance with International Conference on 




Linearity was studied by preparing standard 
solutions at different concentrations from 0.1 
to 10 µg/mL, plotting a graph of concentration 
against peak area, and determining the 




Accuracy was evaluated in triplicate, at three 
different concentrations equivalent to 80, 100, 
and 120% of the active ingredient, by adding 
a known amount of APT standard to a 
sample of known concentration and 
calculating the recovery of APT, RSD (%), 




The precision of the procedure was 
determined by repeatability and intermediate 
precision studies. Repeatability was 
evaluated by performing six determinations at 
the same concentration, during the same 
day, under the same experimental conditions. 
Intermediate precision was evaluated by 
comparing the assays on 3 different days 




The robustness of the method was 
investigated by making small deliberate 
changes in the chromatographic conditions at 
three different levels. The chromatographic 
conditions selected were flow rate (1, 1.1, 
and 0.9 mL/ min), varying column 
temperature (28, 30 and 32 
0
C), and amount 
of methanol in the mobile phase (88, 90, and 
92%). Deliberate variations in method 
parameters had no significant effect on the 
determination of the drug in the 
pharmaceutical dosage form, demonstrating 
that measurements are not susceptible to 




The ruggedness of the method was assessed 
by making six replicate injections of the APT, 
as per the proposed method and the assay of 
APT performed by two analysts in the same 
laboratory, two different columns on same 
system and two different systems. 
 
System suitability  
 
System suitability tests are an integral part of 
liquid chromatographic methods. They are 
used to verify that the resolution and 
reproducibility of the chromatographic system 
are adequate for the analysis to be done. The 
tests are based on the concept that the 
equipment, electronics, analytical operations 
and samples to be analyzed constitute an 
integral system that can be evaluated as 
such. A system suitability test was carried out 
to evaluate the reproducibility of the analytical 
system using five replicate injections of a 
reference solution for the parameters such as 
theoretical plates, tailing factor, limit of 
detection (LOD) and limit of quantification 
(LOQ) were calculated for the proposed 
method as follows  
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Limits of detection (LOD) and of 
quantification (LOQ) 
 
The limits of detection and quantification 
were calculated by the method based on the 
standard deviation (σ) of responses for 
triplicate blank injections and the slope (S) of 
the calibration plot, using the formulae LOD = 
3.3σ/S and LOQ = 10σ/S. 
 
Theoretical plates (n) 
 
This is a measure of the sharpness of the 
peaks and therefore the efficiency of the 
Column. This was calculated using the USP 
method as in Eq 1. 
                                    ……………………. (1) 
 
where wb is the peak width at the base.and t 
= retention time of peak 
 
Tailing factor (T) 
 
This is a measure of the asymmetry of the 
peak 
T = W/2f ..………………………………… (2)  
where W = width at 5 % of the peak height, 
and f = distance between the maximum and 
the leading edge of the peak  
 
Preparation of mobile phase  
 
HPLC grade solvents of methanol and water 
were used for the preparation of the mobile 
phase in a ratio of 90:10 (v/v). The contents 
of the mobile phase were filtered before use 
through a 0.45µm membrane filter, sonicated 
and pumped from the solvent reservoir to the 
column at a flow rate of 1 mL/min.  
 
Preparation of standard solutions  
 
A standard stock solution of  APT was 
prepared by dissolving 10 mg of pure APT in 
100 mL of volumetric flask containing 70 mL 
of methanol ( HPLC grade) and sonicated for 
15 min and then made up to volume with 
methanol to obtain a concentration of  
100µg/mL. Daily working standards of APT 
were prepared by suitable dilution of the 
stock solution with mobile phase. Different 
sets of drug solution were prepared in the 
mobile phase containing APT in a 
concentration range of 0.1 - 10µg/mL. Each 
of the these dilutions (20 µL) was injected six 
times into the column set at a flow rate of 1.0 
mL/min, and the peak area of each of the 
drug concentrations, and the retention times 
were recorded. 
 
Construction of calibration curve  
 
Different concentrations of analyte were 
prepared from the stock solution by taking 
suitable volumes of APT and diluting them to 
obtain the desired concentrations for linearity 
in the range of 0.1 - 10 µg/mL. The prepared 
solutions were filtered through 0.45 µm 
membrane filter and each of the dilutions was 
injected six times into the column. The 
calibration curve for APT was constructed by 
plotting the mean peak area (Y-axis) against 
the concentration (X-axis). It was found to be 
linear in the concentration range 0.1 - 10 
µg/mL with good correlation between 
concentration and mean peak area. 
 
Application of proposed method to solid 
dosage form   
 
Twenty capsules were weighed and their 
contents were removed and mixed 
thoroughly. A sample of the powder 
equivalent to the label claim (10 mg of the 
active ingredient) was mixed with 70 mL of 
methanol and the mixture was allowed to 
stand for 30 min with intermittent sonication 
to ensure complete solubility of the drug. It 
was then filtered through a 0.45 µm 
membrane filter, followed by the addition of 
methanol to the 100 mL mark to obtain a 
stock solution of 100 µg/mL. An aliquot of this 
solution (1 mL) was transferred to a 
volumetric flask and made up to a sufficient 
volume with the mobile phase to give a 
concentration of 10 µg/mL. The prepared 
dilution was injected in triplicate into the 
column to obtain a chromatogram. The drug 
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content of the capsules was quantified from 




Method development  
 
The drug was eluted in the given mobile 
phase at a short retention time (tr) of 4.313 
min. Typical chromatograms of APT are 
shown in Fig 2. 
 
          (2a)                                     (2b) 
 
Fig 2: Typical chromatograms of pure APT (2a) 
and APT in capsules (2b) 
 
Method validation  
 
The method was validated as per 
International Conference on Harmonization 
(ICH) guidelines for the different validation 
parameters. The method was validated for its 





The standard plot for APT was constructed 
by plotting the ratio of the peak area of APT 
to the peak area of the internal standard (Y) 
against concentration (X). It was found to be 
linear with a correlation coefficient (r
2
) of 
0.989 with the linear regression equation 
being, y = 33032x+71501 in the linear range 
of 0.1 - 10 µg/mL, the coefficients of variation 
(CV) based on the peak area ratios for six 
replicate injections, were between 0.12 - 
0.67.  
 
Statistical data of calibration curves  
 
Regression characteristics, namely, standard 
deviation of slope (Sb), RSD of the slope and 
standard deviation of intercept (Sa) were 
250.10, 0.753 and 393.8, respectively. 
 
Precision of the method 
 
The precision results are shown in Table. 1. 
The intraday precision of the method (mean, 
% ± RSD, %) was 100.07 ± 0.85 (n = 6). The 
intermediate precision was evaluated by 
comparing the results obtained on 3 different 
days and between analysts. The value was 
found to be 99.62 ± 1.05 (n = 18). The low 
variability of the experimental values obtained 
for the determination of APT in samples 
indicates that the precision of the method is 
acceptable. 
 
Table 1: Intraday (n = 6) and interday (n = 18) 




Day 1 Day 2 Day 3
a
 
1 100.15 99.00 99.97      
2 100.44 98.43 100.2 
3 101.54 100.40 97.5 
4 100.19 99.98 98.3 
5 99.08 98.39 99.2 






















By spiking previously analysed test solution 
with additional standard drug the recovery of 
the method was found to be 99.56 and 
100.50 %. Values of recovery (%) and RSD 
(%) are listed in the Table. 2. RSD was 
always < 1 %, which indicates that the 
method is accurate. 
 
Content of APT in commercial capsule 
formulation  
 
The assay of commercial APT capsules 
showed that the developed method, shown in 
Table 3, was accurate and reliable, with 
mean drug content of 99.97 % of the labeled 
claim. No interference peaks were found in 
the chromatogram, indicating that the 
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determination of the drug content was free 
from interference by excipients.  
 









1 101.27 100.2 99.65 
2 99.66 99.8 98.9 
3 100.11 101.5 100.13 
Mean  100.35 100.50 99.56 




Ruggedness of the method was evaluated by 
comparing the results of assay of APT 
obtained from two analysts, two systems and 
two columns. RSD was always <2%, which 
indicates the method is rugged. 
 
 
Table 3: Assay data for commercial aprepitant 















The results of the evaluation of the rugged-
ness of the proposed method are shown in 




System suitability parameters were 
established and found to be within acceptable 
limits as indicated in Table 5. The results 
indicate that the proposed method was 
sufficiently robust for normally expected 
variations in chromatographic conditions. 
 
System suitability  
 
To determine the reproducibility of the 
method, system suitability test was 
employed. The tailing factor was 1.223, 
theoretical plates 1188.87, limit of detection 
(LOD) 0.028 and limit of quantification (LOQ) 
0.094.  
 
Specificity of the method 
 
The specificity of the proposed method 
demonstrated that excipients in the capsules 
did not interfere with the drug peak. 
Furthermore, the well-shaped peaks also 
indicate the specificity of the method. 
 
Table 4: Ruggedness of the method 
 
Sample no. Analyst 1 Analyst 2 System 1 System 2 Column 1 Column 2 
1 80.12 80.06 79.20 80.00 80.51 79.10 
2 80.35 80.75 78.74 81.06 82.25 81.01 
3 81.23 79.62 80.32 79.34 80.62 80.00 
4 80.15 80.00 79.98 80.22 80.00 80.00 
5 79.26 80.56 78.71 81.82 81.22 79.21 
6 79.23 78.54 80.00 80.16 80.25 80.76 
Mean ±SD 80.06±0.68 79.92±0.72 79.49±0.64 80.43±0.80 80.81±0.75 80.01±0.71 
%RSD 0.85 0.90 0.80 0.99 0.92 0.89 
Table 5: Robustness of the method 
 
Variation in methanol 
content of mobile phase  
Variation in flow rate 
(mL/min) 













% RSD 0.2 0.1 0.3 0.2 0.1 0.2 0.1 0.4 0.3 
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DISCUSSION 
 
The development of HPLC methods for the 
determination of drugs has received great 
attention in analytical research because of 
their importance in quality control. The 
technique is unique, versatile, universal, 
basic and well-utilized the researchers 
because of its ease of operation. The main 
objective of method development is to 
determine the drug content of formulations as 
well as purity. In analytical research, the time 
and cost of method development and 
validation are of great importance. The 
objective of this study was to develop and 
validate a simple, sensitive, rapid, economic 
and accurate RP-HPLC method for the 
estimation of APT in commercial capsule 
products.  
 
The developed method, using simple HPLC 
grade solvents (methanol and water), had a 
short retention time and high peak symmetry. 
The method developed was validated 
successfully. The selected mobile phase 
system gave a single sharp peak for APT 
without interfering peaks. The retention time 
(tr) of APT was 4.313 min with a tailing factor 
of 1.223. The method was linear in the 
concentration range of 0.2 - 10µg/ml, obeyed 
Beers’ law and the calibration curves showed 
good correlation between concentration and 
peak area.  
 
The method was validated as per ICH 
guidelines for parameters such as accuracy, 
precision, robustness, ruggedness, limit of 
detection (LOD) and limit of quantification 
(LOQ), which indicates that the results 




The results of the study showed that the 
proposed RP-HPLC method for the 
estimation of APT is simple, sensitive, rapid, 
cost-effective and accurate for the 
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